Knight Therapeutics Inc. announced impairment charges for the fourth quarter of 2023. For the period, the company announced impairment of non-current assets of CAD 9,260,000 compared to CAD 21,904,000 a year ago.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
5.91 CAD | +1.55% | +3.14% | +13.87% |
Mar. 22 | Knight Therapeutics Price Target Raised to $7 at RBC | MT |
Mar. 21 | Knight Therapeutics Reports Fourth Quarter Results | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+13.87% | 437M | |
+5.48% | 71.19B | |
+12.55% | 9.3B | |
-13.75% | 5.01B | |
+42.38% | 4.47B | |
+4.51% | 3.96B | |
+21.10% | 2.44B | |
-19.05% | 2.41B | |
-28.72% | 2.23B | |
+11.13% | 2.02B |
- Stock Market
- Equities
- GUD Stock
- News Knight Therapeutics Inc.
- Knight Therapeutics Inc. Announces Impairment Charges for the Fourth Quarter of 2023